Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension - Summary - MDSpire

Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension

  • By

  • Xiaopei Cui

  • Xiaoyu Hu

  • Xiaoteng Qin

  • Haijun Li

  • Xia Xu

  • Hui Liu

  • Qiushang Ji

  • May 21, 2026

Share

Objective:

To evaluate the safety and efficacy of initial triple therapy including selexipag in Chinese patients with pulmonary arterial hypertension (PAH), highlighting its significance in improving treatment outcomes.

Key Findings:
  • last_point
Interpretation:

Triple-targeted therapy including selexipag is safe and effective for improving exercise capacity and right heart function in Chinese PAH patients, suggesting important implications for clinical practice.

Limitations:
  • additional_point
Conclusion:

Selexipag-based initial triple therapy significantly enhances outcomes in PAH patients, suggesting potential long-term benefits, warranting further studies for confirmation.

Original Source(s)

Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension

  • by Xiaopei Cui, Xiaoyu Hu, Xiaoteng Qin, Haijun Li, Xia Xu, Hui Liu, Qiushang Ji

  • May 21, 2026

Related Content

LC9 Scores Tied to Better Lung Health in NHANES Analysis

Cross-sectional study linked higher cardiovascular health scores with fewer respiratory symptoms and higher lung function measures among US adults

Flu Hospitalization Tied to Diabetes Risk

A large English cohort study found influenza hospitalization more than doubled the short-term risk of new-onset diabetes, with prediabetes and critical care admission among the strongest predictors.

Recent Rates of Systemic Treatment for Metastatic NSCLC in Older Adults

In a cohort study reported in JAMA Oncology, Fox et al found that approximately half of older patients with metastatic non–small cell lung cancer (NSCLC) have received systemic therapy in the United S...